Riik: Austraalia
keel: inglise
Allikas: Department of Health (Therapeutic Goods Administration)
mycophenolate mofetil, Quantity: 500 mg
Roche Products Pty Ltd
Injection, powder for
Excipient Ingredients: polysorbate 80; sodium hydroxide; citric acid; hydrochloric acid
Intravenous
4 vials
(S4) Prescription Only Medicine
CellCept is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. CellCept is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.
Visual Identification: WHITE TO OFF-WHITE POWDER.; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 3 Years; Container Temperature: Store below 30 degrees Celsius
Licence status A
2000-02-07
CELLCEPT ® _mycophenolate mofetil_ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about CellCept. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking CellCept against the benefits expected for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT CELLCEPT IS USED FOR CellCept contains the active ingredient mycophenolate mofetil. CellCept belongs to a group of medicines called immunosuppressants. Immunosuppressants are used to prevent the rejection of a transplanted organ and work by stopping your immune system from reacting to the transplanted organ. There are many different types of medicines used to prevent rejection of a transplanted organ. CellCept may be used together with other medicines known as cyclosporin and corticosteroids. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY CELLCEPT HAS BEEN PRESCRIBED FOR YOU. Your doctor may have prescribed CellCept for another reason. CellCept is not addictive. This medicine is only available with a doctor’s prescription. BEFORE YOU TAKE OR ARE GIVEN CELLCEPT _WHEN YOU MUST NOT TAKE IT_ DO NOT TAKE CELLCEPT IF: 1. YOU HAVE AN ALLERGY TO: • CellCept or any of the ingredients listed at the end of this leaflet. • Some of the symptoms of an allergic reaction may include: • shortness of breath • wheezing or difficulty breathing • swelling of the face, lips, tongue or other parts of the body • rash, itching or hives on the skin CELLCEPT IV SOLUTION SHOULD NOT BE GIVEN IF YOU HAVE AN ALLERGY TO POLYSORBATE 80. 2. YOU ARE PREGNANT • CellCept is harmful to an unborn baby when taken by a pregnant woman. • There have been cases of miscarriage and severe birth defects reported when patients have taken CellCept during pregnancy. • You must tell your d Lugege kogu dokumenti
AUSTRALIAN PRODUCT INFORMATION CELLCEPT ® (MYCOPHENOLATE MOFETIL) CellCept 20211130 1 1. NAME OF THE MEDICINE Mycophenolate mofetil 2. QUALITATIVE AND QUANTITATIVE COMPOSITION CellCept 250 mg capsules contain 250 mg mycophenolate mofetil. CellCept 500 mg tablets contain 500 mg mycophenolate mofetil. CellCept 500 mg powder for concentrate for solution for infusion contains 500mg mycophenolate mofetil (as hydrochloride salt). CellCept 1 g/5 ml powder for oral suspension contains 1 g mycophenolate mofetil per 5 mL when reconstituted. For the full list of excipients, see section 6.1. List of excipients. 3. PHARMACEUTICAL FORM CELLCEPT 250MG CAPSULES Capsules, hard. CellCept capsules: oblong, blue/brown, branded with black "CellCept 250" on the capsule cap and "Roche" name on the capsule body. CELLCEPT 500 MG TABLETS Film coated tablets. CellCept tablets: lavender coloured caplet-shaped tablet, engraved with "CellCept 500" on one side and "Roche" name on the other. CELLCEPT 500 MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION Powder for concentrate for solution for infusion. Sterile lyophilised white to off-white powder for infusion. CellCept 500 mg powder for concentrate for solution for infusion must be reconstituted and further diluted with glucose intravenous infusion 5% prior to administration to the patient. Reconstitution and dilution with 5% glucose intravenous infusion as recommended yields a slightly yellow solution of mycophenolate mofetil, 6 mg/mL. CELLCEPT 1 G/5 ML POWDER FOR ORAL SUSPENSION. Powder for oral suspension White to off-white powder for oral suspension 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS CellCept is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. CellCept is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants. 4.2 DOSE AND METHOD OF ADMINISTRATION DOSAGE The initial dose of CellCept should be given as soon as clinically feasible following trans Lugege kogu dokumenti